Clinical Trial Update: Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia [Phase 2]

View source ↗

Summary

Phase 2 long-term safety and efficacy update for momelotinib in various myelofibrosis subtypes; study completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Polycythemia Vera
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Momelotinib (momelotinib)

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2021-02-05